2008 - Metformin plus a lifestyle intervention was more effective than either alone for antipsychotic-induced weight gain

Vaz-Leal, Francisco J.
August 2008
ACP Journal Club;8/19/2008, Vol. 149 Issue 2, p3
Academic Journal
The article focuses on a study regarding the impact of the combination of lifestyle intervention and metformin in reducing antipsychotic-induced weight gain in schizophrenia and presents the author's comments on it. It describes the procedure and the outcomes of the study, wherein randomized placebo-controlled trial was conducted. The author suggests that implementation of pharmacologic and nonpharmacologic preventive measures should be a basic element of treatment schedules in schizophrenia.


Related Articles

  • Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. Fiedorowicz, Jess G.; Miller, Del D.; Bishop, Jeffrey R.; Calarge, Chadi A.; Ellingrod, Vicki L.; Haynes, William G. // Current Psychiatry Reviews;Feb2012, Vol. 8 Issue 1, p25 

    Pharmacological treatments for serious mental illness (SMI) can cause weight gain and adverse metabolic effects. Many second generation antipsychotics and mood stabilizers appear to be particularly problematic in this regard. Several studies have investigated interventions for...

  • COMMENTARY. Vaz-Leal, Francisco J. // Evidence Based Medicine;Oct2008, Vol. 13 Issue 5, p146 

    The author reflects on the implementation of metformin plus lifestyle intervention (LSI) in patients with antipsychotic-associated weight gain. He presents a treatment comparison between patients who receive atypical antipsychotics (AAPs) and those who do not. He states low AAP doses with...

  • Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study. Poyurovsky, Michael; Fuchs, Camil; Pashinian, Artashez; Levi, Aya; Faragian, Sarit; Maayan, Rachel; Gil-Ad, Irit // Psychopharmacology;Jun2007, Vol. 192 Issue 3, p441 

    Search for safe and effective strategies to diminish weight gain associated with second generation antipsychotics (SGAs) is imperative. In the present study, we sought to replicate our preliminary findings, which indicated that coadministration of the selective norepinephrine reuptake inhibitor...

  • Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate. Kern Sliwa, Jennifer; Dong-Jing Fu; Bossie, Cynthia A.; Turkoz, Ibrahim; Alphs, Larry // BMC Psychiatry;2014, Vol. 14 Issue 1, p1 

    Background There is a strong association between weight gain and metabolic events in patients with schizophrenia receiving many of the second-generation antipsychotic agents. We explored the relationship between body mass index (BMI) and metabolic events in patients with schizophrenia receiving...

  • Antibiotics for Severe Acute Malnutrition. Jenson, Hal B. // Infectious Disease Alert;Mar2013, Vol. 32 Issue 6, p63 

    A randomized, double-blind, placebo-controlled clinical trial was conducted from December 2009 through January 2011 at 18 feeding sites in Malawi. This region of oral sub-Saharan Africa has a subsistence farming population with an estimated 11% of adults infected with the human immunodeficiency...

  • Effects of Oral Clonidine in Preventing Postoperative Shivering After General Anesthesia. Mohammadi, Sussan Soltani; Seyedi, Mirsadegh // International Journal of Pharmacology;2007, Vol. 3 Issue 5, p441 

    This randomized controlled study was performed to evaluate the efficacy of oral clonidine; an a 2-agonists which augments the inhibiting control of preoptic anterior hypothalamic region on the shivering center, before operation compared with placebo, in preventing postoperative shivering. Eighty...

  • Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. Miyamoto, S; Miyake, N; Jarskog, L F; Fleischhacker, W W; Lieberman, J A // Molecular Psychiatry;Dec2012, Vol. 17 Issue 12, p1206 

    Since the introduction of chlorpromazine and throughout the development of the new-generation antipsychotic drugs (APDs) beginning with clozapine, the D2 receptor has been the target for the development of APDs. Pharmacologic actions to reduce neurotransmission through the D2 receptor have been...

  • Continued use of antipsychotic drugs increased long-term mortality in patients with Alzheimer disease. Hirsch, Calvin // ACP Journal Club;6/23/2009, Vol. 150 Issue 6, p6 

    The article discusses whether continued treatment with antipsychotic drugs (APDs) increase mortality in patients with Alzheimer disease. A randomized placebo-controlled trial was conducted on 165 patients who lived in nursing or residential homes. The intervention, outcomes and patient follow up...

  • CLINICAL INQUIRIES. Beck, Stacie; Ludwig, Mary Jo; Safranek, Sarah; Guirguis-Blake, Janelle // Journal of Family Practice;Jul2013, Vol. 62 Issue 7, p377 

    The article presents a study which discusses the best treatment of agitation in irreversible demetia. The Agency for Healthcare Research and Quality conducted a meta-analysis of 37 randomized controlled trials (RCTs) on the use of atypical antipsychotics among 5364 patients. Result show that...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics